X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES CIPLA SUVEN LIFESCIENCES/
CIPLA
 
P/E (TTM) x 17.4 24.9 70.0% View Chart
P/BV x 3.5 2.7 131.7% View Chart
Dividend Yield % 0.6 0.6 94.5%  

Financials

 SUVEN LIFESCIENCES   CIPLA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
CIPLA
Mar-18
SUVEN LIFESCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs338663 50.9%   
Low Rs169479 35.4%   
Sales per share (Unadj.) Rs52.1189.0 27.6%  
Earnings per share (Unadj.) Rs6.817.6 38.8%  
Cash flow per share (Unadj.) Rs8.634.0 25.2%  
Dividends per share (Unadj.) Rs1.503.00 50.0%  
Dividend yield (eoy) %0.60.5 112.6%  
Book value per share (Unadj.) Rs65.3176.7 36.9%  
Shares outstanding (eoy) m127.28805.12 15.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.93.0 161.0%   
Avg P/E ratio x37.132.5 114.4%  
P/CF ratio (eoy) x29.616.8 176.3%  
Price / Book Value ratio x3.93.2 120.2%  
Dividend payout %22.017.1 128.8%   
Avg Mkt Cap Rs m32,272459,724 7.0%   
No. of employees `0001.123.6 4.6%   
Total wages/salary Rs m66126,901 2.5%   
Avg. sales/employee Rs Th6,132.26,446.1 95.1%   
Avg. wages/employee Rs Th611.11,139.4 53.6%   
Avg. net profit/employee Rs Th803.5600.0 133.9%   
INCOME DATA
Net Sales Rs m6,635152,193 4.4%  
Other income Rs m2423,577 6.8%   
Total revenues Rs m6,877155,769 4.4%   
Gross profit Rs m1,60428,264 5.7%  
Depreciation Rs m22113,228 1.7%   
Interest Rs m381,142 3.3%   
Profit before tax Rs m1,58717,470 9.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m7182,501 28.7%   
Profit after tax Rs m86914,166 6.1%  
Gross profit margin %24.218.6 130.2%  
Effective tax rate %45.214.3 315.9%   
Net profit margin %13.19.3 140.8%  
BALANCE SHEET DATA
Current assets Rs m6,232108,141 5.8%   
Current liabilities Rs m1,49038,322 3.9%   
Net working cap to sales %71.545.9 155.8%  
Current ratio x4.22.8 148.2%  
Inventory Days Days8697 89.1%  
Debtors Days Days8374 111.0%  
Net fixed assets Rs m4,043109,411 3.7%   
Share capital Rs m1271,610 7.9%   
"Free" reserves Rs m8,183140,682 5.8%   
Net worth Rs m8,310142,292 5.8%   
Long term debt Rs m1836,621 0.0%   
Total assets Rs m10,389228,606 4.5%  
Interest coverage x43.116.3 264.6%   
Debt to equity ratio x00.3 0.8%  
Sales to assets ratio x0.60.7 95.9%   
Return on assets %8.76.7 130.4%  
Return on equity %10.510.0 105.1%  
Return on capital %19.510.0 196.0%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62251,691 10.9%   
Fx outflow Rs m1,79921,033 8.6%   
Net fx Rs m3,82230,658 12.5%   
CASH FLOW
From Operations Rs m35614,628 2.4%  
From Investments Rs m-279-8,540 3.3%  
From Financial Activity Rs m-225-3,855 5.8%  
Net Cashflow Rs m-1482,431 -6.1%  

Share Holding

Indian Promoters % 63.4 16.0 396.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 36.5 26.2 139.3%  
Shareholders   37,287 161,166 23.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   PLETHICO PHARMA  BIOCON   FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Metal Stocks Lag(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is flat.

Related Views on News

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Aug 21, 2019 11:03 AM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS